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The short paper by Michael Retsky and his colleagues in
the current issue of Breast Cancer Research is, I believe,
of revolutionary importance in the history of the
understanding of breast cancer [1]. Unfortunately, its title,
“Hypothesis: Induced angiogenesis after surgery in
premenopausal node-positive breast cancer patients is a
major underlying reason why adjuvant chemotherapy
works particularly well for those patients”, belies this
importance. Therefore, I was delighted to accept the
invitation to write a commentary to draw attention to a
paper, the significance of which, if fully appreciated, might
change the direction of research into breast cancer.
Like all revolutionary ideas it so challenges conventional
belief (dogma) that one can expect a knee jerk rejection
from those who have an intellectual or financial investment
in the received wisdom, to either ignore or react with
irrational anger to its implicit message. What the authors
are in fact suggesting is that the act of surgery kick starts
“latent” metastases of patients with “early” breast cancer
into an active state of vascularization and proliferation.
This not only accounts for the effect described in the title,
but importantly, also explains the paradox of screening in
younger women where we see an excess of breast cancer
deaths in the screened group within the first few years [2].
This observation so enrages the screening zealots that
they indulge in a kind of ideological warfare against
anyone who draws attention to this counter-intuitive
observation [3]. Perhaps now that we have a mechanism
to explain this finding, the more open minded in the
scientific community might begin to believe in it.
What we now have is a new model of the disease that
owes its genesis, in part, to the interpretation of the results
of natural history databases and clinical trials, by way of
hazard rate plots rather than Kaplan Meyer curves.
We can now see a new signal appearing against
background noise, which challenges the assumption of
linear dynamics in favour of non-linear mathematics or
chaos theory [4]. This “signal” is the early peak of hazard
for relapse that follows surgery within 12 to 24 months,
whereas the near constant hazard thereafter might be the
“echo” of the natural history of breast cancer left
unperturbed by surgical interference. If that is true then
the act of wounding the patient by surgery creates a
favourable environment for the sudden transfer of a
micrometatasis from a latent to an active phase.
The most obvious prediction of the model would be that
natural or evolutionary advantageous biological events
following wounding would also favour cancer progression
as a side effect. (It should be remembered in this context
that most cancers are the consequence of ageing beyond
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the age of reproductive activity that in evolutionary terms is
neutral). In fact, work published in 2004 confirms the
similarities in the gene expression of fibroblasts following
wounding to those active in malignant disease [5]. Or as
Weinberg put it, “The way that tumours acquire the ability
to create complex tissues does not involve their de-novo
invention of the complex programme of stromal activation.
Instead they activate a latent, pre-existing wound-healing
programme that is encoded in the normal genome, which
they then use as the strategy for constructing their own
stroma” [6]. With that in mind we can note with no great
surprise a slue of “downstream” epi-phenomena linking
molecular events that favour wound healing to the
progression and prognosis of breast cancer. For example,
HER2 over-expression is closely linked with the
expression of vascular endothelial growth factor (VEGF)
[7], both of which are associated with a poor prognosis.
The fluid from surgical drains is very potent in stimulating
epithelial and endothelial cells and this is directly
proportional to the magnitude of the operation and
indirectly to the age of the patient [8]. Cyclooxygenase
(COX)-2 expression is associated with an aggressive
phenotype of duct carcinoma in situ [9] and the
angiogenicity of circulating malignant cells in the
peripheral blood of breast cancer patients predicts for
early relapse and resistance to chemotherapy [10]. Finally
the paradoxical “curative” effect of adjuvant tamoxifen
might be as much to do with its inhibition of the secretion
of VEGF as to its anti-oestrogenic effect [11].
To my way of thinking the therapeutic consequences of this
belief system go way beyond the modest predictions in the
paper that provoked this commentary and suggest that the
next leap forward would depend on “stabilizing” these
latent metastases with a combination of anti-angiogenic,
anti-proliferative and pro-apoptotic therapies before letting
a surgeon near a patient. Perhaps the fact that I speak as a
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